There are currently 467 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University at Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Social Workers Addressing Firearm Risk
NCT05784662
Recruiting
Aim 2: Evaluate the preliminary efficacy of the SAFR intervention using a randomized controlled trial. An additional 100 practicing social workers (excluding participants from Aim 1) will be recruited, with n = 50 allocated to each arm of the study utilizing block randomization. Participants in the control arm will receive invitations to all surveys but not to the SAFR intervention itself. We will utilize the validated measures from Aim 1 to assess changes on study variables. Results will be ana... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Online Only, Buffalo, New York
Conditions: Gun Violence Prevention
Register for Updates
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
NCT03865472
Recruiting
This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS) works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a form of brain stimulation therapy that controls nerve cell activity, increases blood flow in the brain, and improves cognitive function.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cigarette Smoker, Current Every Day Smoker, Current Smoker
Register for Updates
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
NCT05356182
Recruiting
The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: University at Buffalo / Great Lakes Cancer Care, Buffalo, New York
Conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy
Register for Updates
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439
Recruiting
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Buffalo, New York
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Buffalo General Medical Center, Buffalo, New York
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
NCT05665062
Recruiting
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Roswell Park, Buffalo, New York
Conditions: CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Register for Updates
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
NCT05678998
Recruiting
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Facility Name: Roswell Park Comprehensive Cancer Care, Buffalo, New York
Conditions: Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: The University of Buffalo, Buffalo, New York
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Survivor Mom Companion Comparison Study
NCT06318663
Recruiting
The overall goal of the SMC is to help reduce posttraumatic stress symptomology for pregnant persons with a history of trauma.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Buffalo Prenatal-Perinatal Network, Buffalo, New York
Conditions: Posttraumatic Stress Symptom
Register for Updates
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048
Recruiting
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in Patients with metastatic or unresectable gastric adenocarcinoma (including GEJ tumors) that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+). Patients must have progressed or been intolerant of at least one prior line of chemotherapy + HER2 directed therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Gastric Cancer
Register for Updates
FT576 in Subjects With Multiple Myeloma
NCT05182073
Recruiting
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Roswell Park, Buffalo, New York
Conditions: Multiple Myeloma, Myeloma
Register for Updates